VANCOMYCIN BNM (Boucher & Muir Pty Ltd)
Product name
VANCOMYCIN BNM
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
132 (255 working days)
Active ingredients
Vancomycin hydrochloride
Registration type
New generic medicine
Indication
VANCOMYCIN BNM capsules may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by C. difficile.
Parenteral administration of VANCOMYCIN is not effective for the above indications; therefore, VANCOMYCIN BNM must be given orally. VANCOMYCIN BNM is not effective by the oral route for other types of infection.